AntriaBio

AntriaBio develops novel therapeutic products for the diabetes market.

AntriaBio is a biopharmaceutical company focused on developing novel therapeutic products for the diabetes market. Our development strategy combines FDA-approved pharmaceutical agents with our proprietary delivery technology. Our lead product candidate is AB101, an injectable once-a-week basal insulin for Type 1 and Type 2 diabetes. We believe that our development strategy increases the probability of technical success while reducing safety and efficacy concerns, approval risks, and overall development costs. We also believe that our approach will result in significantly improved and more efficacious therapies with substantial benefits to the global diabetic population.